What does this research mean for the field?

DLX5 is an oncogenic factor in hypopharyngeal squamous cell carcinoma (HPSCC) that correlates with poor prognosis due to its association with an immunosuppressive microenvironment. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 6, 2026European journal of medical research0 citationsOpen Access

Integrating bulk and single cell RNA sequencing to predict the potential therapeutic efficacy of DLX5 in hypopharyngeal squamous cell carcinoma

YJYao JiangChina Medical University LLLianhe LiBeijing Chaoyang Emergency Medical Center HWHongmin WangBeijing Chaoyang Emergency Medical Center

Key Points

The research aims to evaluate the role of DLX5 in hypopharyngeal squamous cell carcinoma and its potential as a therapeutic target.
Conducted bioinformatics analysis to examine DLX5's role in HPSCC.
Performed functional assays to assess the effects of DLX5 on malignant phenotypes.
Analyzed the correlation between DLX5 expression and immune cell types in tumor microenvironment.
DLX5 was found to have an oncogenic role in HPSCC through co-amplification with TP63.
High expression levels of DLX5 are associated with increased immunosuppressive cells like M2 macrophages.
DLX5 expression negatively correlates with antitumor CD8+ T cells, indicating a link to immunosuppression.

Abstract

Through bioinformatics analysis, it was discovered that DLX5 exerts an oncogenic role in HPSCC through co-amplification with TP63 and activation of the MAPK signaling pathway, with functional assays further confirming its promotion of malignant phenotypes. High expression of DLX5 correlates positively with immunosuppressive cells, such as M2 macrophages, and negatively with antitumor CD8+ T cells, indicating an association with an immunosuppressive microenvironment. These findings highlight DLX5 as a key determinant of poor prognosis in HPSCC.

AI에게 질문

Bookmark

View Full Paper